Kornimate/medical-research-clean huggingface dataset:
risk prediction of difficult tracheal intubation in osahs patient

Conditions: Difficult Intubation; Airway Obstruction

Summary: this study evaluates the risk factors for difficult tracheal intubation in in obstructive sleep apnea hypopnea syndrome(osahs) patients undergoing uvulo-palato-pharyngoplast(uppp)

osahs patients are high risk group of difficult tracheal intubation. in clinical application, unexpected difficult tracheal intubation is not rare. difficult airway is a significant problem to these patients and the physicans in terms of mortality and morbidity. this study collects risk factors as physical examinations（including modified mallampati grade, neck circumference, lateral clinical craniofacial assessment and body mass index ,bmi）, stopbang scores, polysommographic parameters (including apnea-hypopnea index, ahi and lowest spo2, lspo2), and special radiographic parameters in head and neck region. by using statistics method, predictive model to manage risks would be established.

Eligibility criteria:
inclusion criteria: * diagnosed as osahs. * receive uppp under general anesthesia in beijing tsinghua changgung hospital * asa grade i or ii exclusion criteria: * asa grade iii or above * had received uppp * had fore-teeth loosed * obstructive sleep apnea hypopnea were caused by hypothyroidism, acromegaly, or vocal cord paralysis.

Keywords: airway management obstructive sleep apnea hypopnea syndrome risk predictive model
a single-blind rct to investigate the effect of a novel herbal patch for the treatment of pf

Conditions: Plantar Fasciitis

Summary: disorders and injuries of tendons and ligaments are some of the most diagnosed musculoskeletal (ms) disorders clinically. nearly half of the 33 million ms disorders reported in the united states each year are tendon and ligament injuries. although most of such injuries are non-fatal, they are severely debilitating, resulting in significant reduction in patient's quality of life, loss of productivity, and considerable costs to the healthcare system. among all tendon and ligament disorders and injuries, tendon and ligament overuse disorders are the most common and incapacitating ones. tendinopathy is a painful tendon overuse disorder, which increases with population aging. it has been estimated that about 30% of consultations for ms complaints in a general practice were related to tendinopathy. the affected tendon is presented with local tenderness, swelling and pain, causing physical disability of the affected individual. the affected tendon degenerates and finally ruptures. common sites of tendinopathy include supraspinatus, common wrist extensor, flexor tendon, patellar tendon, and achilles tendon. the outcomes of both conservative treatments and surgeries are not satisfactory, with recurrent pain and tendon retear after surgery. plantar fasciitis is a chronic painful, degenerative condition of the plantar fascia. it is caused by repetitive traumas at its origin on the calcaneus. plantar fascia is a thick, ribbon-like fibrous ligament that connects the medial calcaneal tubercle to the heads of the metatarsal bones. it contributes to the support of the foot arch by acting as a tie-rod, where it undergoes tension when the foot bears weight. therefore, although plantar fascia is anatomically defined as a ligament, it functions similar to a tendon. this study aims to conduct a randomized controlled study to test the efficacy of cdam patch for the treatment of plantar fasciitis in patients.


Eligibility criteria:
inclusion criteria: * male and female with age 18-65 * unilateral or bilateral * heel pain for more than 6 weeks' duration * vas score ≥ 5 * signed informed consent. exclusion criteria: * known chronic disease or receiving long-term medications affecting bone metabolism including bps * contraindication to alendronate therapy such as poor dental fitness * acl injury less than 6 weeks * injury on duty cases * patients who have undergone arthroscopy or open surgery in the index knee in the last 12 months * other associated injuries (fractures and other ligament involvement such as neurovascular bundles injury) * chondral lesion with concomitant intervention * presence of x-ray features of osteoarthritis including decrease in joint space, presence of osteophytes and subchondral cysts * neurological deficit * pregnant or breastfeeding * inability to give informed consent

Keywords: plantar fasciitis herbal patch
adding ketamine to levobupivacaine in paravertebral block in thoracotomy

Conditions: Ketamine; Levobupivacaine; Paravertebral Block; Acute Pain; Chronic Pain

Summary: to evaluate the role of adding ketamine to levobupivacaine in pvb on acute and chronic pain in thoracotomy

several adjuvants have been added to them to enhance the effects of those blocks. dexamethasone, morphine, dexmedetomidine, clonidine, ketamine, and magnesium sulphate are some of them. results are variable. ketamine blocks n-methyl-d-aspartate (nmda) receptors in the spinal cord. it is also considered to influence voltage sensitive calcium ions channels, opioid receptors, and monoaminergic receptors. therefore, it is considered overall to affect nociception.

Eligibility criteria:
inclusion criteria: * age 18-75 years. * both sexes. * asa (american society of anesthesiology) physical status ii-iii. * scheduled for open thoracotomy. exclusion criteria: * contraindications to or failed paravertebral block . * body mass index (bmi) \>35 kg/m2. * the likelihood of postoperative mechanical ventilation. * patients with coagulopathy, poorly controlled diabetes mellitus, depression or other psychiatric disorders that required antidepressant drugs, alcohol, or recreational drug addiction. * hypersensitivity to ketamine or levobupivacaine.
evaluation of laser treatment for benign pigmented lesions by non-invasive, cellular resolution optical coherence tomography

Conditions: Benign Pigmented Lesions

Summary: in recent years, with the maturity of laser technology, laser therapy is one of the popular options for the treatment of pigment diseases. the absorption spectrum of melanin ranges from 300 to 1,000 nm. in past studies, the 532 nm q-switched nd:yag laser is effective for the treatment of superficial melanin. but there are still some side effects in laser treatment, such as post-inflammation pigmentation (pih), depigmentation, skin redness, etc., and pih is particularly likely to occur on darker skin. however, there is still no good evidence as to what factors or laser treatments can cause pih. therefore, in this study, we will use apollovue® s100 image system (apollovue® s100 image system is a medical device class ii) to scan before and after skin of laser treatment to observe the changes in the skin condition. by observing and analyzing these changes, as a evaluation of predictors or prognostic factors after laser treatment and whether pih will occur.


Eligibility criteria:
inclusion criteria: * age ≧ 20 * both gender are accepted * subject with pigmented diseases * the pigmented lesions which participating the trial were not treated in the last 12 months * accepts not to expose the face to sunlight or artificial uv rays during the study * is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits * during the trial period, willing to use the maintenance and sunscreen products provided in this trial for care exclusion criteria: * pregnant woman or woman wishing to be pregnant during the study, or during breastfeeding period * has any condition which, in the investigator's opinion, would make it unsafe for participating in this research study * has systemic skin disorders or infections * is enrolled or accepted other investigational drug or medical device

Keywords: optical coherence tomograohy non-invasive image system cellular level resolution full-field oct hyperpigmentation
inspiratory effort in covid-19

Conditions: Acute Respiratory Failure; Covid19

Summary: this study aims at assessing esophageal pressure in patients with acute respiratory failure due to covid-19 undergoing non invasive respiratory support.


Eligibility criteria:
inclusion criteria: * covid-19 * acute respiratory failure undergoing non-invasive respiratory support exclusion criteria: * need for immediate endotracheal intubation * chronic respiratory diseases

Keywords: acute respiratory failure esophageal pressure non invasive respiratory support covid-19
evaluation of modafinil as a cocaine treatment medication and interactions with cocaine - 1

Conditions: Cocaine-Related Disorders; Drug Administration Schedule; Infusions, Intravenous

Summary: the purpose of this study is to evaluate modafinil, a cocaine treatment medication, and its interactions with intravenous (iv) cocaine.

placebo-controlled, escalating dose drug interaction study using a total of 12 cocaine users at a single site. study duration will include four infusion sessions: 1) screening/baseline; 2) baseline; 3) 400mg/day steady-state modafinil; 4) 800 mg/day steady state modafinil. infusion session will be 2 days in duration.

Eligibility criteria:
inclusion criteria: dependent on cocaine; non-treatment seeking; male or female; dsm-4 criteria for cocaine abuse or dependence; at least 18 years of age but no older than 45 non-pregnant females using adequate birth control; capable of providing written informed consent; able to comply with protocol requirements. exclusion criteria: additional criteria available during screening at the site
mixed urinary incontinence symptoms before and after treatment with botox and bulkamid

Conditions: Mixed Incontinence, Urge and Stress

Summary: this study compares mixed urinary incontinence symptoms before and after a combined treatment with botox and bulkamid. eligible for the study are adult females with a mixed urinary incontinence, having both urgency urinary symptoms and stress urinary symptoms.


Eligibility criteria:
inclusion criteria: 1. women aged ≥ 18 years. 2. clinically diagnosed therapy-refractory mixed urinary incontinence (mui) based on cough test, urodynamic evaluation, 3-day micturition diary, incontinence-questionnaire with visual analog scales for sui and uui. 3. all criteria for the indication to treat patient with botox are met. 4. all criteria for the indication to treat patient with bulkamid are met. 5. participant has given informed consent exclusion criteria: 1. all contraindications for bulkamid or botox 2. previous treatment with botulinum toxin (within last 3 months) 3. previous treatment with bulkamid or other bulking agent (within last 3 months) 4. participant is pregnant or lactating 5. current urinary tract infection (in which case this has to be treated first before patient might be included) 6. residual urine of \> 100 ml

Keywords: urgency urinary incontinence stress urinary incontinence botulinum toxin a bulkamid
study of psychosexual impact of cancer-related infertility in women: third party reproductive assistance

Conditions: Cervical Cancer; Endometrial Cancer; Leukemia; Non-Hodgkin's Lymphoma; Uterine Cancer; Vaginal Cancer; Infertility

Summary: this study aims to learn about the needs and feelings of women who are infertile. being infertile means not being able to have a child without the help of a third party. there are other options for building a family. the researchers are interested in the participants' thoughts about these options and want to learn about the experiences of infertile women due to cancer treatment as well as women who are infertile due to other causes. the researchers hope that what they learn will allow them to better care for infertile women in the future.

as part of this study, you will be asked to fill out a series of questionnaires. these questions will ask about your feelings, sexual function, quality of life, and ideas about reproductive options. we will also ask some questions about you, your health, and your medical history. you can choose to answer these questions either at one of your doctor visits or over the telephone. you can decide the best way to complete this assessment.

Eligibility criteria:
inclusion criteria: study group of gynecologic cancer survivors and bmt/smt cancer survivors: * history of a primary diagnosis of gynecologic cancer or history of any primary malignancy treated with bmt/sct * no evidence of disease for at least one year * at least 18 years of age not greater than 49 years of age at time of study recruitment * no other cancer history * have impaired fertility: lack of uterus but intact ovaries or lack of ovaries or lack of ovarian function based on the fsh determination but intact uterus * have not started or have not completed childbearing * able and willing to provide informed consent * ability to comprehend and complete questionnaire in english comparison group of non-cancer infertile women awaiting egg (oocyte) donation: * no cancer history * at least 18 years of age not greater than 49 years of age at time of study recruitment * in ovarian failure and on a waiting list for egg (oocyte) donation * have not started or have not completed childbearing * able and willing to provide informed consent * ability to comprehend and complete questionnaire in english exclusion criteria: * inability to participate in an informed consent process * patients with a psychiatric disorder precluding response to the survey
alcohol, behavior, and brain imaging

Conditions: Alcohol Drinking; Binge Drinking; Drinking Behavior; Substance-Related Disorders; Ethanol; Physiological Effects of Drugs; Central Nervous System Depressants

Summary: to evaluate the relationship of extraversion to both the acute subjective and behavioral effects of alcohol, and the neural reactivity to the anticipation of reward.


Eligibility criteria:
inclusion criteria: * 21-29 years old * 7-30 alcoholic drinks per week (as reported on phq or tlfb) * at least one binge episode (4 for females/5 for males) per month * no 'flushing' reaction to alcohol * females must be on birth control or in the beginning of follicular phase (1-14 days after start of menstruation) * bmi 19-26 * high school education or greater, fluent in english * no night shift work * no current or past year axis i psychiatric disorder including drug/alcohol dependence * no current psychopharmacological treatment * no lifetime adhd or prescription for adhd medication * no abnormal ekg, cardiovascular illness, high blood pressure * no medical condition or pharmacological treatment for which alcohol is contraindicated * not pregnant, lactating, or planning to become pregnant * smoke \<6 cigarettes per day * no previous participation in studies that have used the stop task (except idac) o previous stop task studies: goi, cap, stem, jam, maci, pac, cam
clinical and experimental studies to improve radiotherapy outcome in aids cancer patients

Conditions: Cancer of the Cervix

Summary: the researchers plan: * to undertake clinical studies of radiotherapy with or without the administration of the chemotherapeutic agent cisplatin, known to be a radiosensitizer; * to perform pre-clinical studies of the radiosensitivity of human fibroblasts and cervical cancer cell lines in culture, with or without the addition of various hiv proteins or protease inhibitors, in order to determine the extent of any cellular radiosensitizing properties of these molecules; * to develop strategies for sensitizing tumour cells to radiation, specifically by down-regulating specific viral proteins that are known to be factors associated with resistance to radiotherapy.

clinical study addresses the question of whether radiotherapy plus weekly cisplatin offers an advantage over the same radiotherapy given alone in aids patients with cervix cancer. external beam radiotherapy is used with 50 gy in 25 daily fractions (last interim analysis, october 2005) suggested lowering the total dose down to 46 gy in 23 daily fractions). brachytherapy component was specified as either 30 gy of ldr in a single fraction or 3 fractions of 8 gy using hdr. cisplatin was administered weekly at a dose of 30 mg/sqm.

Eligibility criteria:
inclusion criteria: * cancer of the cervix * aids exclusion criteria: * unable to give informed consent

Keywords: cervical cancer aids external beam radiotherapy brachytherapy cisplatin
differences in extracellular vesicles from adipose tissue of individuals with obesity.

Conditions: Obesity

Summary: our society is characterized by a strong increase in the prevalence of obesity, which often causes the development of cardiovascular and metabolic diseases such as type 2 diabetes. the way(s) obesity is responsible for these diseases, is still insufficiently understood. this study therefore examines the content of human fat tissue storage location- and cell type-specific extracellular vesicles (evs) in lean and obese individuals, and the possible connection with sex, insulin sensitivity, and the blood-brain barrier.

this study focuses on unraveling the fundamental differences in communication via extracellular vesicles (evs) derived from fat cells and immune cells in terms of fat tissue storage location and sex among individuals with and without obesity. the study hypothesizes that the differences in ev profiles, originating from corresponding in vitro differentiated hmads and ex vivo isolated adult fat cells and immune cells, among individuals with and without obesity can be related to sex and/or fat tissue storage location. additionally, the effect of the isolated evs on the blood-brain barrier function is also investigated.

Eligibility criteria:
individuals with obesity - inclusion criteria: * caucasian adults with obesity that have a body mass index (bmi) of at least 35 kg/m\^2 and are scheduled for their first bariatric surgery. * final male/female ratio of this study is 1:1 * minimal knowledge of dutch to read and understand the informed consent. individuals with obesity - exclusion criteria: * smoking and/or drug abuse * cardiovascular diseases (including but not limited to implanted aids like a pacemaker or defibrillator) * lung and/or kidney diseases * brain and/or nerve diseases * malignant diseases (e.g. cancer) individuals without obesity (lean) - inclusion criteria * caucasian adults with obesity that have a body mass index (bmi) of between 18 and 24.9 kg/m\^2 and are scheduled for abdominal surgery * female only * minimal knowledge of dutch to read and understand the informed consent. individuals without obesity (lean) - exclusion criteria * smoking and/or drug abuse * cardiovascular diseases (including but not limited to implanted aids like a pacemaker or defibrillator) * lung and/or kidney diseases * brain and/or nerve diseases * endocrine diseases like type 2 diabetes * malignant diseases (e.g. cancer)
international first-in-human study of the enlightn generation 2 system in patients with drug-resistant uncontrolled hypertension

Conditions: Hypertension; Renal Denervation

Summary: the purpose of this first-in-human clinical investigation is to evaluate the safety and performance of the st. jude medical enlightn™ generation 2 renal denervation system for the treatment of patients with drug-resistant uncontrolled hypertension.


Eligibility criteria:
inclusion criteria: * subject is ≥ 18 and ≤ 80 years of age at time of consent * subject must be able and willing to provide written informed consent * subject must be able and willing to comply with the required follow-up schedule * subject has office systolic blood pressure ≥ 160 mmhg at confirmatory visit * subject has a daytime mean systolic ambulatory blood pressure \> 135 mmhg during the two week screening period * subject has an office systolic blood pressure that remains ≥160 mmhg despite the stable use of ≥3 antihypertensive medications concurrently at maximally tolerated doses, of which one is a diuretic or subject was previously on diuretic but documented to be diuretic intolerant, for a minimum of 14 days prior to the procedure and with an expectation to maintain for a minimum of 180 days post procedure. exclusion criteria: * subject has significant renovascular abnormalities such as renal artery stenosis \> 30% in either renal artery * subject has undergone prior renal angioplasty, renal denervation, indwelling renal stents, and/or abdominal aortic stent grafts * subject has hemodynamically significant valvular heart disease as determined by the study investigator * subject has a life expectancy less than 12 months, as determined by a study investigator * subject is participating in another clinical study which has the potential to impact their hypertension management (pharmaceutical/device/homeopathic) * subject is pregnant, nursing, or of childbearing potential and is not using adequate contraceptive methods * subject has active systemic infection * subject has renal arteries with diameter(s) \< 4 mm in diameter or \<20 mm in length * subject has an estimated glomerular filtrate rate (egfr) \<45 ml/min per 1.73 m2 using the modified diet in renal disease (mdrd) formula * subject has diabetes mellitus type i * subject has multiple main renal arteries in either kidney * subject has an identified secondary cause of hypertension (for example, including, but not limited to, polycystic kidney disease, cushing's syndrome, aldosteronism) * subject has evidence of significant abdominal aortic aneurysm (defined as maximum diameter of \>4 cm) * subject has had a myocardial infarction, unstable angina pectoris or cerebrovascular accident less than 180 days prior to enrollment * subject is expected to have cardiovascular intervention within the next 180 days * subject has a condition which would interfere with the accurate interpretation of the study objectives including but not limited to a large arm diameter that is unable to accommodate the blood pressure cuff or arrhythmia that interferes with automatic pulse sensing.
real life effectiveness in patients with not optimally controlled asthma

Conditions: Asthma

Summary: in real life, the investigators will be using different strategies including smart therapy or other ics/laba (medium and high dose) therapy and measure the efficacy for asthma control.

1. all not-well controlled asthma patients would include the study. 2. we will compare three ways of asthma control including smart, fixed doses with regular doses and fixed doses with higher doses 3. we will evaluate the efficacy/safety for these not-well controlled patients.

Eligibility criteria:
inclusion criteria: * asthma not well control exclusion criteria: * copd

Keywords: asthma smart fixed dose
prehabilitation in prostate cancer patients, teleprehabtrial

Conditions: Prostate Cancer

Summary: localized prostate cancer is commonly treated with radical prostatectomy (rp). following surgery adverse effects such as urinary incontinence, erectile dysfunction associated with decreased quality of life and decreased physical function are common. traditionally, interventions to reduce these adverse effects are introduced postoperatively. however, a growing body of literature shows the benefit of interventions prior to surgery to enhance treatment success, known as prehabilitation. hence, the main purpose of this study is to develop and investigate the feasibility of prehabilitation using telehealth, to implement several interventions prior to elective rp.


Eligibility criteria:
inclusion criteria: * male \> 18 years * diagnosed with prostate cancer and referred to robot assisted nerve sparring rp * adequacy in written and spoken danish * cognitively well-functioning * able to understand the study procedures and willing to provide signed informed consent exclusion criteria: * severe comorbidities that would prevent the patient from exercising, e.g. recent fractures, severe heart disease or neurological disorders. * no possibility to use a smartphone or tablet.